IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by Worldquant Millennium Advisors LLC

Worldquant Millennium Advisors LLC boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 1,537.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 235,444 shares of the medical research company's stock after buying an additional 221,064 shares during the period. Worldquant Millennium Advisors LLC owned 0.13% of IQVIA worth $46,267,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in IQV. JPMorgan Chase & Co. grew its holdings in IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock valued at $437,378,000 after buying an additional 583,396 shares in the last quarter. Merit Financial Group LLC grew its holdings in IQVIA by 32.8% in the 4th quarter. Merit Financial Group LLC now owns 4,293 shares of the medical research company's stock valued at $844,000 after buying an additional 1,060 shares in the last quarter. Client 1ST Advisory Group LLC purchased a new stake in IQVIA in the 4th quarter valued at $614,000. UMB Bank n.a. grew its holdings in IQVIA by 72.8% in the 4th quarter. UMB Bank n.a. now owns 401 shares of the medical research company's stock valued at $79,000 after buying an additional 169 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in IQVIA by 16.8% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,172 shares of the medical research company's stock valued at $230,000 after buying an additional 169 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Performance

Shares of NYSE IQV opened at $143.32 on Tuesday. The stock has a fifty day moving average price of $158.99 and a two-hundred day moving average price of $185.26. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a market cap of $24.79 billion, a P/E ratio of 19.11, a PEG ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a 1 year low of $135.97 and a 1 year high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.63 by $0.07. The business had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The company's revenue was up 2.5% compared to the same quarter last year. During the same period last year, the company posted $2.54 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on IQV. JPMorgan Chase & Co. dropped their target price on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday. Morgan Stanley upped their price target on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. Citigroup decreased their price target on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Finally, BTIG Research lowered IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $228.14.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.